Ken Herrmann, MD, MBA
Ken Herrmann, MD, MBA
Ken Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Germany. Herrmann is Section Editor of The Journal of Nuclear Medicine and Imaging Editor of European Urology.
Disclosures: Honoraria and/or fees from AdvanCell, Aktis Oncology, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent Therapeutics, Curium Pharma, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, MSD, Molecular Partners, Novartis (Advanced Accelerator Applications), NVision, Pfizer, Pentixapharm, POINT Biopharma, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, SOFIE Biosciences, Telix, Theragnostics, and Y-mAbs Therapeutics.
View content featuring Herrmann:
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.